<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636971</url>
  </required_header>
  <id_info>
    <org_study_id>CER-VD No 273/13</org_study_id>
    <nct_id>NCT03636971</nct_id>
  </id_info>
  <brief_title>Gait Analysis Following Knee Viscosupplementation</brief_title>
  <official_title>Gait Analysis Following Single-shot Hyaluronic Acid Supplementation: a Pilot Randomised Double-blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigitte Jolles, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, double-blind, randomised trial that investigates which gait parameters are
      more sensitive following a single bolus injection of hyaluronic acid with mannitol,
      hyaluronic acid with sorbitol, or saline placebo for knee osteoarthritis. Outcome measures
      are gait analysis through a inertial sensors (Physilog), Knee Society Score (KSS), University
      of California Los Angeles (UCLA) activity-scale and EuroQol 5Dimensions. Follow-up will be of
      4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2013</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 30, 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gait Speed</measure>
    <time_frame>4 weeks following injection</time_frame>
    <description>measured over the 30m of the test trial using an inertial-based system (Physilog, BioAGM, CH) following a previously validated protocol. Spatiotemporal parameters are analysed (i.e. gait speed, cadence, limping...)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KSS specific knee mobility scale</measure>
    <time_frame>4 weeks following injection</time_frame>
    <description>Knee specific clinician-based mobility scale based on clinical examination. Score interpretation: 80-100 Excellent, Score 70-79 Good, Score 60-69 Fair, score below 60 Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQool -5 dimensions self-reported scale of quality of life</measure>
    <time_frame>4 weeks following injection</time_frame>
    <description>The EQ-5D-5L essentially consists on the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises 5dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.Each dimension comprising the EQ-5D descriptive system is divided into 5levels of perceived problems:Level 1:no problem Level 2:slight problems Level 3: moderate problems Level 4:severe problems Level 5: extreme problems. A unique health state is defined by combining 1 level from each of the 5 dimensions.A total of 3125 possible health states is defined in this way. Each state is referred to in terms of a 5 digit code.
The EQ VAS records the patient's self-rated health on a 20cm vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCLA- activity scale</measure>
    <time_frame>4 weeks following injection</time_frame>
    <description>Activity numerical ordinal scale ranging from 1 (lowest) to 10 (highest)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) pain</measure>
    <time_frame>4 weeks following injection</time_frame>
    <description>continual numerical scale (0-10), 0 the best score (no pain) and 10 the worst.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Gait</condition>
  <condition>Knee Osteoarthritis</condition>
  <condition>Injection</condition>
  <arm_group>
    <arm_group_label>hyaluronic acid with mannitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hyaluronic acid with sorbitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyaluronic acid with mannitol</intervention_name>
    <description>single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)</description>
    <arm_group_label>hyaluronic acid with mannitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyaluronic acid with sorbitol</intervention_name>
    <description>single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)</description>
    <arm_group_label>hyaluronic acid with sorbitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>single shot injection of saline, same volume</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of primary knee OA Ahlbäck II-III and signed consent forms.

        Exclusion Criteria:

          -  recent history of infection, diabetes, neurological impairment, chronic venous or
             lymphatic stasis, pain medication of level 2 or 3, psychiatric conditions,
             contraindications for HA joint injection and previous HA or steroid injections in the
             last six months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte Brigitte</last_name>
    <role>Study Chair</role>
    <affiliation>CHUV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUV - Hopital Orthopedique</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>Brigitte Jolles, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Sorbitol</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

